Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression

Molecular Cancer Therapeutics

Volumn 3, Issue 4, 2004, Pages 499-511

  Swenson, Stephen ^a   Costa, Fritz ^a   Minea, Radu ^a   Sherwin, Russell P ^a   Ernst, William ^b   Fujii, Gary ^b   Yang, Dongyun ^a   Markland Jr , Francis S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Molecular Express Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CONTORTROSTATIN; DISINTEGRIN; INTEGRIN; LIPOSOME; SNAKE VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENCAPSULATION; ENDOTHELIUM CELL; IMMUNE DEFICIENCY; IMMUNOGENICITY; LABORATORY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SNAKE; THROMBOCYTE RELEASE REACTION; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

AGKISTRODON; ANIMALS; BLOOD PLATELETS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DISEASE PROGRESSION; DISINTEGRINS; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LIPOSOMES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SNAKE VENOMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444329286     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1998. Bethesda, MD: National Cancer Institute; 2001.
2. Moiseeva N, Swenson SD, Markland FS Jr, Bau R. Purification, crystallization and preliminary X-ray analysis of the disintegrin contortrostatin from Agkistrodon contortrix contortrix snake venom. Acta Crystallogr D Biol Crystallogr, 2002;58:2122-4.
3. 3 integrins. FEBS Lett, 1996;391:139-43.
4. Trikha M, De Clerck YA, Markland FS. Contortrostatin, a snake venom disintegrin, inhibits β1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res, 1994;54: 4993-8.
5. Zhou Q, Nakada MT, Arnold C, Markland FS. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis, 1999;3:259-69.
6. Zhou Q, Sherwin RP, Parrish C, et al. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat, 2000;61:249-60.
7. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res, 1994; 54:3352-6.
8. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Nat Acad Sci USA, 1998;95:4607-12.
9. Woodle MC. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids, 1993;64:249-62.
10. Fujii G. Liposomal amphotericin B (AmBisome): realization of the drug delivery concept. New York: Marcel Dekker; 1996. p. 491.
11. Langer R. Drug delivery and targeting. Nature, 1998;392:5-10.
12. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol, 2001;28:32-40.
13. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res, 1994;54: 987-92.
14. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep, 2001;3:156-62.
15. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol, 1999;17:1435-41.
16. O'Byrne KJ, Thomas AL, Sharma RA, et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer, 2002;87:15-20.
17. Russo D, Piccaluga PP, Michieli M, et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol, 2002;81:462-6.
18. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs, 1997;4(54 Suppl):22-9.
19. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol, 1997; 15:987-93.
20. Golubkov V, Hawes D, Markland FS Jr. Angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis, 2003; In press.
21. 3-mediated tyrosine phosphorylation of CAS and FAK in tumor cells. J Cell Biochem, 2000;79:28-37.
22. 5. Biochem Biophys Res Commun, 2000; 267:350-5.
23. Markland FS, Zhou Q. Snake venom disintegrin: an effective inhibitor of breast cancer growth and dissemination. Am Chem Soc Symp Ser, 2000;745:262-82.
24. Zhou Q, Ritter M, Markland FS. Contortrostatin, a snake venom protein, which is an inhibitor of breast cancer progression. Mol Biol Cell, 1996;7 Suppl:425a.
25. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 1995;96:1815-22.
26. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994; 79:1157-64.
27. 3 for angiogenesis. Science, 1994;264:569-71.
28. 5 to promote tumor cell dissemination in vivo. J Clin Invest, 1997;99:1390-8.
29. v integrins. Science, 1995;270:1500-2.
30. 1 integrins. Proc Natl Acad Sci USA, 2003; 100:4766-71.
31. Kim S, Bell K, Mouse SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin a5b1 with the central cell-binding domain of fibronectin. Am J Pathol, 2000;156:1345-62.
32. 1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vasc Pharmacol, 2003;40:77-89.
33. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the avb3 and a5b1 integrins. Am J Pathol, 2000;156:1673-83.
34. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer, 1996;32A:2423-9.
35. 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer, 2003;104:496-503.
36. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J, 2001;7:427-36.
37. Kieran MW, Billett A Antiangiogenesis therapy. Current and future agents. Hematol Oncol Clin North Am, 2001;15:835-51, viii.
38. Marx J. Angiogenesis. A boost for tumor starvation. Science, 2003; 301:452-4.
39. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003;21:60-5.
40. Anonymous. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer, 2003;3:85-8.
41. Zhou Q, Shieh KY, Markland FS. Contortrostatin (CN), a dimeric disintegrin inhibits invasion of ovarian cancer by blocking integrin avb5. Proc Am Assoc Cancer Res, 2000;41:800.
42. Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res, 1994;73:39-52.
43. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res, 1990;50:717-21.
44. Fujii G, Chang JE, Coley T, Steere B. The formation of amphotericin B ion channels in lipid bilayers. Biochemistry, 1997;36:4959-68.
45. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem, 1985;150:76-85.
46. Hunter WM, Greenwood FC. The preparation of 131 I-labeled human growth hormone of high specific activity. Nature, 1962;194: 495-503.
47. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970;277:680-5.
48. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res, 1985;45:584-90.
49. DeClerck YA, Yean TD, Chan D, Shimoda H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res, 1991;51:2151-7.
50. Pileri SA, Roncador G, Ceccarelli C, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol, 1997;183:116-23.
51. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. Int J Cancer, 1993;55:739-44.
52. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem, 1986;55:1037-57.
53. Giancotti FG, Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta, 1994;1198:47-64.
54. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol, 1996;8:724-30.
55. Ritter MR, Markland FS Jr. Contortrostatin activates ERK2 and tyrosine phosphorylation events via distinct pathways. Biochem Biophys Res Commun, 2000;274:142-8.
56. Ritter MR, Markland FS Jr. Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin. Toxicon, 2001; 39:283-9.
57. Trikha M, Flores M, Markland FS. Disintegrins inhibit mammary carcinoma binding to extracellular matrix proteins. FASEB J, 1994;8:A873.
58. Hashizurne H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 2000;156:1363-80.
59. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol, 2002;29:3-9.
60. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res, 1990;354A: 317-30.
61. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res, 1998;58: 1408-16.
62. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer, 2002;2:83-90.
63. Dvorak H, Nagy J, Dvorak J, Dvorak A. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol, 1988;133:95-109.
64. Newman PJ. The role of PECAM-1 in vascular cell biology. Ann NY Acad Sci, 1994;714:165-74.
65. Ferrero E, Ferrero ME, Pardi R, Zocchi MR. The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. FEBS Lett, 1995;374:323-6.
66. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol, 1990;110:1227-37.
67. Newman PJ, Berndt MC, Gorski J, et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science, 1990;247:1219-22.
68. Schimmenti LA, Yan HC, Madri JA, Albelda SM. Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration. J Cell Physiol, 1992;153:417-28.
69. Muller WA, Weigl SA, Deng X, Phillips DM, PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med, 1993;178:449-60.
70. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol, 1997; 151:671-7.
71. Giatromanolaki A, Koukourakis MI, Theodossiou D, et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res, 1997;3: 2485-92.
72. Sheu J-R, Teng C-M, Huang T-F. Triflavin, an RGD-containing antiplatelet pepticle, binds to GPIIIa of ADP-stimulated platelets. Biochem Biophys Res Commun, 1992;189:1236-42.
73. Kang IC, Lee YD, Kim DS. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res, 1999;59:3754-60.
74. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol, 1992;3:65-71.
75. Folkman J. Tumor angiogenesis. In: Weichselbaum RR, editor. Cancer medicine. Baltimore: Williams and Wilkins; 1997. Vol. 1, p. 181-204.
76. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med, 1996;2: 689-92.
77. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997;88:277-85.
78. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997;390:404-7.
79. Kojima N, Ueno N, Takano M, et al. Effect of Adriamycin entrapped by sulfatide-containing liposomes on ovarian tumor-bearing nude mice. Biotechnol Appl Bioc, 1986;8:471-8.
80. Sampedro F, Partika J, Santalo P, Molins-Pujol AM, Bonal J, Perez-Soler R. Liposomes as carriers of different new lipophilic antitumor drugs: a preliminary report. J Microencapsul, 1994;11:309-18.
81. Kim SI, Kim KS, Kim HS, et al. Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. Cancer Res, 2003;63:6458-62.
82. Yamada T, Kidera A. Tailoring echistatin to possess higher affinity for integrin α(IIb) β(3). FEBS Lett, 1996;387:11-5.
83. Yeh CH, Pang HC, Yih JB, Huang TF. A new short chain RGD-containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation. Biochim Biophys Acta, 1998;1425:493-504.
84. Oshikawa K, Terada S. Ussuristatin 2, a novel KGD-bearing disintegrin from Agkistrodon ussuriensis venom. J Biochem, 1999;125:31-5.